5:45 PM
 | 
Oct 16, 2012
 |  BC Extra  |  Company News

Map resubmits Levadex NDA to FDA

Map Pharmaceuticals Inc. (NASDAQ:MAPP) resubmitted an NDA to FDA for Levadex to treat migraines in adults. The company said the application addresses issues raised in a March complete response...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >